To the Editor:

In the coronavirus disease 2019 (COVID-19) pandemic, the Extracorporeal Life Support Organization (ELSO) registry reported that 1,571 patients were treated with venovenous extracorporeal membrane oxygenation (VV-ECMO) to maintain adequate oxygen delivery.[@bib0001] It seems important to remember that oxygen delivery (DaO~2~) is determined by both the pulmonary and circulatory systems. This becomes apparent in VV-ECMO treatment.

In VV-ECMO- treated patients, arterial oxygen saturation (SaO~2~) is dependent on VV-ECMO (blood) flow- to- cardiac output (CO) ratio and pulmonary shunt. Changes in CO impact the ratio of fully oxygenated blood from VV-ECMO and desaturated blood from the body owing to pulmonary shunt and oxygen consumption. Hence, if CO increases at stable VV-ECMO flow and pulmonary function, the admixture of less oxygenated blood increases and SaO~2~ decreases. Nevertheless, this leads to an improvement in DaO~2~ because DaO~2~ mainly depends on CO instead of SaO~2~ (DaO~2~ = CO × \[Hemoglobin × SaO~2~ × 1.36 + \[paO~2~ × 0.003\]\], red arrows in [Fig 1](#fig0001){ref-type="fig"} , A).Fig 1Changes in oxygen-related parameters according to variation of cardiac output. (A) Plot of a patient data management system. Changes in SpO~2~ related to CO at stable VV-ECMO flow; *red arrows* show changes in CO and consecutive changes in SvO~2~ and SpO~2~. Arrow 1: DO~2~ = 1,049 mL/min, CO = 9.9 L/min, SpO~2~ = 93%, and hemoglobin (Hb) = 8.5 g/dL; Arrow 2: DO~2~ = 713 mL/min, CO 6.5 L/min, SpO~2~ = 92%, and Hb = 8.9 g/dL; Arrow 3: DO~2~ = 792 mL/min, CO = 8.2 L/min, SpO~2~ = 81%, and Hb = 8.9 g/dL (dissolved oxgyen is neglected and SpO~2~ instead of SaO~2~ was used for approximation). (B) Relationship between cardiac output, DaO~2,~ arterial oxygenation saturtation (SaO~2~), pulmonalarterial oxygenation (SpaO~2~), SvO~2~ (mixed venous saturation before VV-ECMO flow admixture) at stable VV-ECMO flow. Nadir SaO~2~ and SpaO~2~ are shown at CO = 2.18 \* VV-ECMO flow. (Oxygen consumption: 250 mL/min; Hb: 8 g/dL; pulmonary shunt: 50%; ECMO flow: 3 L/min; arterial pCO~2~: 40 mmHg; ECMO recirculation rate: 10%; F~I~O~2~ at ECMO 50%, F~I~O~2~ at lung: 50%). CO, cardiac output (L/min); HR, heart rate (beats/min); SpO~2~, saturation of peripheral oxygen (%); VV-ECMO flow, venovenous extracorporeal membrane oxygenation (L/min).Fig 1

According to specifications by Zanella et al., we simulated the interaction of respective variables and (patho-)physiologic conditions in a VV-ECMO simulator (Simulink, Matlab 2020a, Mathworks).[@bib0002] This model confirmed that increased CO inevitably leads to increased DaO~2~ despite decreased SaO~2~, if VV-ECMO flow and pulmonary function remain unchanged. Moreover, it showed associated changes of oxygen saturation in the pulmonary artery (SpaO~2~) and SaO~2~ ([Fig 1](#fig0001){ref-type="fig"}, B), as observed in a clinical setting of a COVID-19 patient on VV-ECMO ([Fig 1](#fig0001){ref-type="fig"}, A). Our VV-ECMO simulation showed the SaO~2~ follows a curvilinear course with a nadir saturation, where CO is approximately twice as high as VV-ECMO flow (VV-ECMO- to- CO ratio about 1:2.18, [Fig 1](#fig0001){ref-type="fig"}, B). Because of this nadir, increased SaO~2~ may not indicate increased DaO~2~, and on the left side from the nadir, DaO~2~ will inevitably fall despite increasing SaO~2~. On the right side from the nadir, DaO~2~ rises in parallel with increasing SaO~2~, mainly due to increased CO ([Fig 1](#fig0001){ref-type="fig"}, B). The position of the nadir SaO~2~ varies with VV-ECMO flow, CO, and their ratio, and further with recirculation rate and pulmonary shunt. This dissociation between SaO~2~ and DaO~2~ was previously shown for beta-blocker therapy in VV-ECMO treatment, which may improve arterial oxygenation but reduces CO and DaO~2~.[@bib0003]

In conclusion, increased SaO~2~ may be a sign of decreased CO (approaching the ECMO flow rate) in VV-ECMO treatment and may therefore have adverse effects on DaO~2~. The recognition of this underlying physiologic process seems paramount to optimize oxygen delivery in VV-ECMO-treated critically ill patients.
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